Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.09%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | -1.18 | Pending | -- |
| 2026-05-13 | -0.96 | -1.08 | -12.8% |
| 2026-02-26 | -1.16 | -0.70 | +39.8% |
| 2025-11-13 | -1.77 | -1.30 | +26.4% |
| 2025-08-07 | -1.58 | -2.00 | -26.3% |
| 2025-05-15 | -2.40 | -2.50 | -4.2% |
| 2025-03-31 | -2.38 | -2.50 | -4.9% |
| 2024-11-07 | -2.18 | -2.40 | -9.9% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$32.6M | -$33.2M | — | -$33.2M | -1.08 |
| 2025-12-31 | — | -$19.3M | -$23.3M | — | -$23.3M | — |
| 2025-09-30 | — | -$25.6M | -$26.0M | — | -$26.0M | -1.30 |
| 2025-06-30 | — | -$26.8M | -$27.0M | — | -$27.1M | -2.00 |
| 2025-03-31 | — | -$25.5M | -$26.8M | — | -$26.8M | -2.51 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2025-06-13 | NASH DUANE D | Officer and Director | 20,000 | $16.7K |
| 2025-06-05 | NEERMANN JOERG | Director | 100,000 | $76.7K |
| 2025-06-05 | TARDIO JASON | President | 12,512 | $9.9K |
| 2025-06-05 | TARDIO JASON | President | 12,512 | $9.9K |
| 2025-06-04 | VITT DANIEL | Chief Executive Officer | 15,000 | $11.6K |
| 2025-06-04 | VITT DANIEL | Officer and Director | 15,000 | $11.6K |
| 2025-06-03 | WHALEY GLENN | Chief Financial Officer | 45,000 | $32.1K |
| 2025-06-03 | RUDICK RICHARD ALAN | Director | 143,075 | $100.0K |
| 2025-05-30 | WHALEY GLENN | Chief Financial Officer | 25,000 | $14.0K |
| 2024-11-12 | RUDICK RICHARD ALAN | Director | 87,300 | $100.4K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Marshall Wace LLP | 953.0K | $12.4M | 0.1% |
| Aberdeen Group plc | 824.4K | $10.8M | 0.1% |
| BVF Inc. | 765.3K | $10.0M | 0.1% |
| Vanguard Capital Management LLC | 513.8K | $6.7M | 0.0% |
| Soleus Capital Management, L.P. | 450.0K | $5.9M | 0.0% |
| Laurion Capital Management, LP | 388.2K | $5.1M | 0.0% |
| Millennium Management Llc | 378.0K | $4.9M | 0.0% |
| Morgan Stanley | 328.9K | $4.3M | 0.0% |
| Nantahala Capital Management, LLC | 250.6K | $3.3M | 0.0% |
| 683 Capital Management LLC | 245.0K | $3.2M | 0.0% |
-$8.7M
-23.56
8
$146.0K
1.00
4.34
0.1%
92
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $-1.18 | Pending | — |
| 2026-05-13 | $-0.96 | $-1.08 | -12.8% |
| 2026-02-26 | $-1.16 | $-0.70 | +39.8% |
| 2025-11-13 | $-1.77 | $-1.30 | +26.4% |
| 2025-08-07 | $-1.58 | $-2.00 | -26.3% |
| 2025-05-15 | $-2.40 | $-2.50 | -4.2% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($44.67, 9 analysts) | |||
| 10 | $121.60 | +$325.10 (267%) | 17.9R |
| 50 | $608.00 | +$1,625.50 (267%) | 17.9R |
| 100 | $1,216.00 | +$3,251.00 (267%) | 17.9R |
- Elevated short interest (4.34 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ARKG | 0.347 |
| HQH | 0.334 |
| ARKK | 0.319 |
| IWM | 0.312 |
| BLSH | 0.296 |
| Ticker | Correlation |
|---|---|
| ULVR.L | -0.180 |
| KYIVW | -0.173 |
| 4326.SR | -0.152 |
| BAES.L | -0.142 |
| IMB.L | -0.136 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.